Udeme Ekpenyong Ekrikpo

Udeme Ekpenyong Ekrikpo

Auto-generated profile, based on publicly available information

Udeme Ekpenyong Ekrikpo

Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Kidney International Reports
Verified
Journal Article
Open access
OAOluwatoyin I. Ameh
Oluwatoyin I. Ameh
UEUdeme E. Ekrikpo
Udeme E. Ekrikpo
AKAndre Pascal Kengne
Andre Pascal Kengne
The epidemiologic transition occurring in low- and middle-income countries (LMICs) has led to a surge in chronic kidney disease (CKD) prevalence because of a combination of highly prevalent chronic noncommunicable diseases (NCDs) and communicable diseases (CDs). The progressive rise in CKD prevalence in LMICs threatens the existing weak health systems in these countries as care for advanced CKD remains largely unavailable and unaffordable. An interplay of low literacy levels, poor health-seeking behavior, inadequate health care funding, weak health systems, and lack of skilled nephrology workforce has made it difficult for adequate CKD preventive measures to be implemented. Primary, secondary, and tertiary prevention measures need to be instituted in LMICs by a collaboration of governmental and nongovernmental organizations to stem this tide and help prevent deaths from other NCDs that share similar risk factors with CKD. For these to be effective, locally relevant knowledge is needed to contextualize existing prevention and control solutions, or to develop novel and more appropriate solutions for LMICs.

2 July 2024 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
OAOluseyi Ademola Adejumo
Oluseyi Ademola Adejumo
IEImuetinyan Rashida Edeki
Imuetinyan Rashida Edeki
DODapo Sunday Oyedepo
Dapo Sunday Oyedepo
JFJoshua Falade
Joshua Falade
OYOlawale Elijah Yisau
Olawale Elijah Yisau
UEUdeme Ekpenyong Ekrikpo
Udeme Ekpenyong Ekrikpo
Background Chronic kidney disease (CKD) is commonly associated with psychosocial problems, especially depression, contributing to poor overall outcomes. Depression has not been given adequate priority in the management of CKD patients despite its significant adverse impact on all major outcomes. This systematic review and meta-analysis determined the pooled prevalence of clinical depression in the global CKD population and sub-populations. Methods PubMed, African Journals Online (AJOL), and EMBASE were systematically searched to identify published articles with relevant data. The pooled prevalence of clinical depression in the global CKD population was determined using random effects meta-analytic techniques. The study protocol was registered with PROSPERO (CRD42022382708). Results Sixty-five articles were included in this review, comprising 80,932 individuals with CKD from 27 countries. The participants' mean age ranged from 11.0 to 76.3 years. Most (70.4%) of the studies had medium methodological quality. The overall pooled prevalence of depression was 26.5% (95% CI 23.1–30.1%). Studies using the Diagnostic Statistical Manual for Mental Diseases (DSM) and International Classification of Disease (ICD) returned a pooled prevalence of 25.5% and 39.6%, respectively, p = 0.03. There was a significant difference in the pooled prevalence across regions; p = 0.002.The prevalence of depression was higher among individuals on chronic hemodialysis compared to pre-dialysis patients (29.9% versus 18.5%; p = 0.01) and among those on hemodialysis compared to peritoneal dialysis (30.6% versus 20.4%; p = 0.04). There was no significant difference between adults and children (26.8% versus 15.9%, p = 0.21). There was an increasing temporal trend in depression prevalence, though this did not achieve statistical significance (p = 0.16). Conclusion Depression is common in patients with CKD. The findings of this study highlight the need for clinicians to make efforts to evaluate individuals with CKD for depression, especially those with advanced stages of the disease. Graphical abstract

6 April 2022 in Kidney International Reports
Verified
Journal Article
Open access
IOIkechi G. Okpechi
Ikechi G. Okpechi
FCFergus J. Caskey
Fergus J. Caskey
AGAbduzhappar Gaipov
Abduzhappar Gaipov
ETElliot K. Tannor
Elliot K. Tannor
JNJean Jacques Noubiap
Jean Jacques Noubiap
VJVivekanand Jha
Vivekanand Jha
Decisions on whether to screen for chronic kidney disease (CKD) or not remain contentious in nephrology. This study provides a global overview of early CKD identification efforts. Guidelines for scoping reviews were followed and studies were identified by searching MEDLINE, EMBASE, Cochrane Library, CINAHL, ISI Web of Science, and PsycINFO. Data extracted from included studies focused on the following 4 themes: study population, measurement methods, interventions used, and available policies. We identified 290 CKD screening and detection programs from 83 countries. Overall sample size was 3.72 million (North East Asia: 1.19 million), detection of CKD was the aim in 97.6%, 63.1% used population-based screening methods, and only 12.4% were in rural populations. Reported CKD prevalence (stages 3–5) was higher in targeted- (14.8%) than population-based studies (8.0%). Number of persons needed to screen (NNS) to identify 1 case was also lower in targeted studies (7 vs. 13). Single measurements (80%) and the combination of estimation of glomerular filtration rate with a urine test (albuminuria/proteinuria) (71.4%) were frequently used to detect CKD. Only 2.8% of studies included an intervention such as pharmacotherapy in identified cases. Policies on early identification were available in 30.1% of countries included. Methods for early CKD identification vary worldwide, often leading to wide variations in the reported prevalence. Efforts to standardize measurement methods for early detection focusing on high-risk populations and ensuring appropriate interventions are available to those identified with CKD will improve the value of programs and improve patient outcomes.

8 April 2024 in Kidney International Supplements
Verified
Journal Article
Closed access
VCViviane Calice-Silva
Viviane Calice-Silva
JNJavier A. Neyra
Javier A. Neyra
AFAlejandro Ferreiro Fuentes
Alejandro Ferreiro Fuentes
KMKrissia Kamile Singer Wallbach Massai
Krissia Kamile Singer Wallbach Massai
SASilvia Arruebo
Silvia Arruebo
DZDeenaz Zaidi
Deenaz Zaidi

1 October 2020 in International Journal of Nephrology and Renovascular Disease
Verified
Journal Article
Open access
PDF file
OAOluwatoyin Idaomeh Ameh
Oluwatoyin Idaomeh Ameh
UEUdeme Ekrikpo
Udeme Ekrikpo
ABAminu Bello
Aminu Bello
IOIkechi Okpechi
Ikechi Okpechi
The incidence and prevalence of chronic kidney disease (CKD) and kidney failure continues to increase worldwide, especially in resource-limited countries. Many countries in this category already have a massive burden of communicable diseases, as well as socio-economic and socio-demographic challenges. The rising CKD burden and exorbitant economic cost associated with treatment are mainly responsible for the alarming mortality rate associated with kidney disease in these regions. There is often poor risk factor (diabetes and hypertension) and CKD awareness in these countries and limited availability and affordability of treatment options. Given these observations, early disease detection and preventive measures remain the best options for disease management in resource-limited settings. Primary, secondary and tertiary preventive strategies need to be enhanced and should particularly include measures to increase awareness, regular assessment to detect hypertension, diabetes and albuminuria, options for early referral of identified patients to a nephrologist and options for conservative kidney management where kidney replacement therapies may not be available or indicated. Much is still needed to be done by governments in these regions, especially regarding healthcare funding, improving the primary healthcare systems and enhancing non-communicable disease detection and treatment programs as these will have effects on kidney care in these regions.

1 January 2017 in International Journal of Nephrology and Renovascular Disease
Verified
Journal Article
Open access
PDF file
NWNicola Wearne
Nicola Wearne
KKKajiru Kilonzo
Kajiru Kilonzo
EEEmmanuel Effa
Emmanuel Effa
BDBianca Davidson
Bianca Davidson
PNPeter Nourse
Peter Nourse
IOIkechi G Okpechi
Ikechi G Okpechi
Chronic kidney disease is a major public health problem that continues to show an unrelenting global increase in prevalence. The prevalence of chronic kidney disease has been predicted to grow the fastest in low- to middle-income countries (LMICs). There is evidence that people living in LMICs have the highest need for renal replacement therapy (RRT) despite the lowest access to various modalities of treatment. As continuous ambulatory peritoneal dialysis (CAPD) does not require advanced technologies, much infrastructure, or need for dialysis staff support, it should be an ideal form of RRT in LMICs, particularly for those living in remote areas. However, CAPD is scarcely available in many LMICs, and even where available, there are several hurdles to be confronted regarding patient selection for this modality. High cost of CAPD due to unavailability of fluids, low patient education and motivation, low remuneration for nephrologists, lack of expertise/experience for catheter insertion and management of complications, presence of associated comorbid diseases, and various socio-demographic factors contribute significantly toward reduced patient selection for CAPD. Cost of CAPD fluids seems to be a major constraint given that many countries do not have the capacity to manufacture fluids but instead rely heavily on fluids imported from developed countries. There is need to invest in fluid manufacturing (either nationally or regionally) in LMICs to improve uptake of patients treated with CAPD. Workforce training and retraining will be necessary to ensure that there is coordination of CAPD programs and increase the use of protocols designed to improve CAPD outcomes such as insertion of catheters, treatment of peritonitis, and treatment of complications associated with CAPD. Training of nephrology workforce in CAPD will increase workforce experience and make CAPD a more acceptable RRT modality with improved outcomes.